Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.31 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.31 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.31 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25758574 | 1.00 | CHRM1 (0.35) | CHRM1MAPTTP53CES1CACNB4 | |
| SCHEMBL25758503 | 0.87 | MAPT (0.39) | CHRM1MAPTTP53CES1PGR | |
| SCHEMBL25758621 | 0.87 | MAPT (0.39) | CHRM1MAPTTP53CES1PGR | |
| SCHEMBL25758624 | 0.81 | BRD4 (0.33) | CHRM1MAPTTP53CHRNB2CHRNA4 | |
| SCHEMBL23835725 | 0.80 | MAPT (0.47) | CHRM1MAPTTP53CES1CACNB4 | |
| SCHEMBL25758635 | 0.80 | MAOB (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL24019652 | 0.80 | MAPT (0.47) | CHRM1MAPTTP53CES1CACNB4 | |
| SCHEMBL15723713 | 0.78 | SNCA (0.37) | CHRM1MAPTTP53 | |
| SCHEMBL15723614 | 0.75 | HTR5A (0.36) | MAPT | |
| SCHEMBL25758588 | 0.75 | HTR5A (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CHRM1 4882/4885MAPT 2276/4885TP53 527/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CHRM1 4881/4885MAPT 2314/4885TP53 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.